Recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy: a phase Ib trial.

Abstract

We evaluated the toxic, hematopoietic, and immunomodulatory effects of recombinant human granulocyte-macrophage colony-stimulating factor (rHuGM-CSF). The rHuGM-CSF was administered at doses up to 50 micrograms/kg by daily 2-hour intravenous infusions to 11 patients with advanced malignancy. It induced dose-related increases in cells of the myeloid series, but it had no significant effect on reticulocyte or platelet counts. Bone marrow cellularity increased with higher doses of rHuGM-CSF, but there was a dose-related decrease in the number of colony-forming units--granulocyte-monocyte--and colony-forming units--granulocyte-erythrocyte-monocyte-megakaryocyte--per 10(5) bone marrow cells. The rHuGM-CSF caused transient increased expression of CD11b and CD16 on granulocytes but increased expression of HLA-DR and decreased expression of the high-affinity Fc receptor on monocytes and no change in monocyte production of H2O2. Thus, rHuGM-CSF has potent effects on granulocyte, eosinophil, and monocyte numbers in the peripheral blood and bone marrow. In addition, it enhances the expression of monocyte and granulocyte activation-associated surface markers.

• Authors: R G Steis, L A VanderMolen, D L Longo, J W Clark, J W Smith 2nd, W C Kopp, F W Ruscetti, S P Creekmore, L J Elwood, J Hursey
• Journal: Journal of the National Cancer Institute (J Natl Cancer Inst) Vol. 82 Issue 8 Pg. 697-703 (Apr 18 1990) ISSN: 0027-8874 [Print] United States
• PMID: 2138680 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Antigens, Differentiation
• Colony-Stimulating Factors
• Growth Substances
• HLA-DR Antigens
• Macrophage-1 Antigen
• Receptors, Fc
• Receptors, IgG
• Receptors, Leukocyte-Adhesion
• Recombinant Proteins
• Granulocyte-Macrophage Colony-Stimulating Factor

Topics

• Antigens, Differentiation (analysis)
• Blood Cell Count
• Bone Marrow (drug effects)
• Colony-Stimulating Factors (adverse effects, therapeutic use)
• Drug Evaluation
• Granulocyte-Macrophage Colony-Stimulating Factor
• Granulocytes (drug effects, immunology)
• Growth Substances (adverse effects, therapeutic use)
• HLA-DR Antigens (analysis)
• Hematopoiesis (drug effects)
• Humans
• Macrophage-1 Antigen
• Monocytes (drug effects, immunology)
• Neoplasms (therapy)
• Receptors, Fc (analysis)
• Receptors, IgG
• Receptors, Leukocyte-Adhesion (analysis)
• Recombinant Proteins (adverse effects, therapeutic use)